Latest Mergers And Acquisitions News

Acrow Limited reports a record FY25 with sales up 23%, driven by an 83% jump in its Industrial Access division, now half of group revenue. Despite soft formwork markets, strategic acquisitions and growth initiatives underpin a confident outlook.

Acrow Limited reported a 23% revenue increase to $265.1 million for FY25, driven by strong growth in its Industrial Access division and key acquisitions. Despite a slight dip in earnings per share, the company declared a fully franked final dividend of 2.95 cents per share.

Activeport Group has successfully closed a fully underwritten rights issue, raising approximately $2.5 million to support its telecommunications software ambitions. The offer included free attaching options, signaling confidence in future growth.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Platinum Asia Investments has finalized its scheme of arrangement, transferring shares to an ETF structure and delisting from the ASX. Shareholders now hold units in the Platinum Asia Fund Complex ETF as the company undergoes a significant restructure.

Symal Group Limited reported a robust FY25 with revenue and earnings growth exceeding Prospectus forecasts, underpinned by strategic acquisitions and a strong pipeline of contracts.

Symal Group has outperformed its FY25 earnings forecasts, driven by strong project margins and strategic acquisitions, setting a robust foundation for FY26 growth.

Symal Group Limited reports a strong first year as an ASX-listed company, exceeding earnings forecasts and advancing its growth through key acquisitions and sustainability initiatives.

Ophir High Conviction Fund reported a robust financial year ending June 2025, with net assets rising nearly 15% and operating profit more than doubling. The Fund’s concentrated portfolio strategy delivered a 24% net return, comfortably outperforming its benchmark.

Platinum Capital Limited reported a 24% drop in net profit for FY2025, underperforming its benchmark, while announcing a strategic withdrawal of a merger scheme and initiating a substantial share buy-back alongside significant board changes.

Following the completion of a scheme of arrangement, Platinum Asia Fund Complex ETF (ASX – PAXX) has issued over 67 million new units, significantly expanding its capital base and setting the stage for increased market activity.